Denali Therapeutics Inc.
DNLI
$15.49
$0.261.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.34% | -30.62% | 3.95% | -7.89% | -154.00% |
| Total Depreciation and Amortization | 103.71% | 48.57% | -342.58% | 2.35% | -15.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.88% | 1,005.08% | 101.44% | 8.84% | -0.61% |
| Change in Net Operating Assets | 385.41% | -38.73% | 80.46% | 788.70% | 97.39% |
| Cash from Operations | 17.45% | -15.71% | 15.15% | 32.31% | 19.39% |
| Capital Expenditure | 10.61% | -136.19% | -127.83% | -87.81% | 18.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.95% | 105.28% | 135.51% | -5.28% | -40.57% |
| Cash from Investing | 60.23% | 104.14% | 135.75% | -7.19% | -41.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.95% | -99.88% | -11.69% | 138.20% | -25.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -75.98% | -100.75% | -188.59% | -844.74% | -25.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 497.38% | -75.08% | 503.37% | -0.51% | -77.93% |